Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oric Pharmaceuticals (ORIC)
NASDAQ:ORIC
Holding ORIC?
Track your performance easily
ORIC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.27 - $16.65
Previous Close$10.67
Volume969.28K
Average Volume (3M)571.22K
Market Cap
$752.69M
Enterprise Value$466.28M
Total Cash (Recent Filing)$286.41M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Nov 04, 2024EPS Estimate
-$0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.76
Shares Outstanding70,542,476
10 Day Avg. Volume523,845
30 Day Avg. Volume571,222
Standard Deviation0.25
R-Squared0.04
Alpha-0.00335
Financial Highlights & Ratios
Price to Book (P/B)2.40
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.00
Forecast
1Y Price Target
$20.20Price Target Upside81.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Oric Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsUpcoming catalysts include updated Phase 1b results for ORIC-114 and enrollment in three expansion cohorts for NSCLC patients with specific mutations.
Financial StabilityORIC ended 2Q24 with $308.5M in cash, cash equivalents, and marketable securities, which should provide an operational runway into late 2026.
PartnershipCollaboration inked with OpenBench, a pioneer in AI-enabled success-driven small molecule discovery partnerships, to enrich early discovery efforts against an undisclosed target identified by ORIC's resistance platform to target cancer-specific vulnerabilities.
Bears Say
Clinical DataNegative clinical data with pipeline candidates could impact the stock adversely.
Clinical DevelopmentInability to advance ORIC-114 and ORIC-944 in clinical development is a potential risk.
Clinical TrialsDelays in moving into pivotal clinical trials in various cancer indications could pose significant risks.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ORIC FAQ
What was Oric Pharmaceuticals’s price range in the past 12 months?
Oric Pharmaceuticals lowest stock price was $5.27 and its highest was $16.65 in the past 12 months.
What is Oric Pharmaceuticals’s market cap?
Currently, no data Available
When is Oric Pharmaceuticals’s upcoming earnings report date?
Oric Pharmaceuticals’s upcoming earnings report date is Nov 04, 2024 which is in 45 days.
How were Oric Pharmaceuticals’s earnings last quarter?
Oric Pharmaceuticals released its earnings results on Aug 12, 2024. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.412 by -$0.038.
Is Oric Pharmaceuticals overvalued?
According to Wall Street analysts Oric Pharmaceuticals’s price is currently Undervalued.
Does Oric Pharmaceuticals pay dividends?
Oric Pharmaceuticals does not currently pay dividends.
What is Oric Pharmaceuticals’s EPS estimate?
Oric Pharmaceuticals’s EPS estimate is -$0.49.
How many shares outstanding does Oric Pharmaceuticals have?
Oric Pharmaceuticals has 70,542,470 shares outstanding.
What happened to Oric Pharmaceuticals’s price movement after its last earnings report?
Oric Pharmaceuticals reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.412. Following the earnings report the stock price went up 6.763%.
Which hedge fund is a major shareholder of Oric Pharmaceuticals?
Among the largest hedge funds holding Oric Pharmaceuticals’s share is Viking Global Investors LP. It holds Oric Pharmaceuticals’s shares valued at 28M.
---
Oric Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.20 (81.00% Upside)
$20.20 (81.00% Upside)
Blogger Sentiment
Bullish
ORIC Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.8%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
28.09%
12-Months-Change
Fundamentals
Return on Equity
-38.79%
Trailing 12-Months
Asset Growth
12.71%
Trailing 12-Months
Company Description
Oric Pharmaceuticals
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101 and ORIC-533.
---
ORIC Stock 12 Month Forecast
Average Price Target
$20.20
▲(81.00% Upside)
Technical Analysis
Best Analysts Covering ORIC
1 Year
1 Year Success Rate
10/18 ratings generated profit
1 Year Average Return
+3.19%
reiterated a buy rating 2 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +3.19% per trade.
---